Somatic Mutation of BAP1 Can Lead to Expression Loss in Non-Small Cell Lung Carcinoma: Next Generation Sequencing and IHC Analysis in A Large Single Institute Cohort

1. Murali, R, Wiesner, T, Scolyer, RA. Tumours associated with BAP1 mutations. Pathology. 2013;45:116-126.
Google Scholar | Crossref | Medline2. Carbone, M, Harbour, JW, Brugarolas, J, et al. Biological mechanisms and clinical significance of BAP1 mutations in human cancer. Cancer Discov. 2020;10:1103-1120.
Google Scholar | Crossref | Medline3. Carbone, M, Ferris, LK, Baumann, F, et al. BAP1 Cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med. 2012;10:179.
Google Scholar | Crossref | Medline4. Masclef, L, Ahmed, O, Estavoyer, B, et al. Roles and mechanisms of BAP1 deubiquitinase in tumor suppression. Cell Death Differ. 2021;28:606-625.
Google Scholar | Crossref | Medline5. Louie, BH, Kurzrock, R. BAP1: not just a BRCA1-associated protein. Cancer Treat Rev. 2020;90:102091.
Google Scholar | Crossref | Medline6. LaFave, LM, Béguelin, W, Koche, R, et al. Loss of BAP1 function leads to EZH2-dependent transformation. Nat Med. 2015;21:1344-1349.
Google Scholar | Crossref | Medline7. Di Nunno, V, Frega, G, Santoni, M, et al. BAP1 In solid tumors. Future Oncol. 2019;15:2151-2162.
Google Scholar | Crossref | Medline8. Okonska, A, Felley-Bosco, E. BAP1 Missense mutations in cancer: friend or foe? Trends Cancer. 2019;5:659-662.
Google Scholar | Crossref | Medline9. Masoomian, B, Shields, JA, Shields, CL. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol. 2018;30:102-109.
Google Scholar | Crossref | Medline10. Zhang, AJ, Rush, PS, Tsao, H, Duncan, LM. BRCA1-associated Protein (BAP1)-inactivated melanocytic tumors. J Cutan Pathol. 2019;46:965-972.
Google Scholar | Crossref | Medline11. Betti, M, Aspesi, A, Biasi, A, et al. CDKN2A And BAP1 germline mutations predispose to melanoma and mesothelioma. Cancer Lett. 2016;378:120-130.
Google Scholar | Crossref | Medline12. Hiroshima, K, Wu, D, Hamakawa, S, et al. HEG1, BAP1, and MTAP are useful in cytologic diagnosis of malignant mesothelioma with effusion. Diagn Cytopathol. 2021;49:622-632.
Google Scholar | Crossref | Medline13. Cigognetti, M, Lonardi, S, Fisogni, S, et al. BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations. Mod Pathol. 2015;28:1043-1057.
Google Scholar | Crossref | Medline14. De Rienzo, A, Chirieac, LR, Hung, YP, et al. Large-scale analysis of BAP1 expression reveals novel associations with clinical and molecular features of malignant pleural mesothelioma. J Pathol. 2021;253:68-79.
Google Scholar | Crossref | Medline15. Shinozaki-Ushiku, A, Ushiku, T, Morita, S, Anraku, M, Nakajima, J, Fukayama, M. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma. Histopathology. 2017;70:722-733.
Google Scholar | Crossref | Medline16. Yoshikawa, Y, Sato, A, Tsujimura, T, et al. Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma. Cancer Sci. 2012;103:868-874.
Google Scholar | Crossref | Medline17. Bott, M, Brevet, M, Taylor, BS, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011;43(7):668-672.
Google Scholar | Crossref | Medline | ISI18. Kluzek, K, Srebniak, MI, Majer, W, et al. Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA. Oncotarget. 2017;8(2):28558-28574.
Google Scholar | Crossref | Medline19. Peña-Llopis, S, Vega-Rubín-de-Celis, S, Liao, A, et al. BAP1 Loss defines a new class of renal cell carcinoma. Nat Genet. 2012;44(7):751-759.
Google Scholar | Crossref | Medline20. Gallan, AJ, Parilla, M, Segal, J, Ritterhouse, L, Antic, T. BAP1-mutated Clear cell renal cell carcinoma. Am J Clin Pathol. 2021;155(5):718-728.
Google Scholar | Crossref | Medline21. Jiao, Y, Pawlik, TM, Anders, RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45(12):1470-1473.
Google Scholar | Crossref | Medline | ISI22. Yaziji, H, Battifora, H, Barry, TS, et al. Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity. Mod Pathol. 2006;19(4):514-523.
Google Scholar | Crossref | Medline | ISI23. Kaur, G, Nijhawan, R, Gupta, N, Singh, N, Rajwanshi, A. Pleural fluid cytology samples in cases of suspected lung cancer: an experience from a tertiary care centre. Diagn Cytopathol. 2017;45(3):195-201.
Google Scholar | Crossref | Medline24. Andrici, J, Sheen, A, Sioson, L, et al. Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology. Mod Pathol. 2015;28(7):1360-1368.
Google Scholar | Crossref | Medline25. Cozzi, I, Oprescu, FA, Rullo, E, Ascoli, V. Loss of BRCA1-associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions. Diagn Cytopathol. 2021;49(5):622-632.
Google Scholar | Medline26. Althakfi, W, Gazzo, S, Blanchet, M, et al. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens. Cytopathology. 2020;31(5):5-11.
Google Scholar | Crossref | Medline27. Davidson, B, Tötsch, M, Wohlschlaeger, J, Hager, T, Pinamonti, M. The diagnostic role of BAP1 in serous effusions. Hum Pathol. 2018;79(9):122-126.
Google Scholar | Crossref | Medline28. Andrici, J, Parkhill, TR, Jung, J, et al. Loss of expression of BAP1 is very rare in non-small cell lung carcinoma. Pathology. 2016;48(suppl1):336-340.
Google Scholar | Crossref | Medline29. Owen, D, Sheffield, BS, Ionescu, D, Churg, A. Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer. Hum Pathol. 2017;60(2):82-85.
Google Scholar | Crossref | Medline30. Lih, CJ, Harrington, RD, Sims, DJ, et al. Analytical validation of the next-generation sequencing assay for a nationwide signal-finding clinical trial: molecular analysis for therapy choice clinical trial. J Mol Diagn. 2017;19(3):313-327.
Google Scholar | Crossref | Medline31. van Hemel, BM, Suurmeijer, AJ. Effective application of the methanol-based PreservCyt(™) fixative and the Cellient(™) automated cell block processor to diagnostic cytopathology, immunocytochemistry, and molecular biology. Diagn Cytopathol. 2013;41(8):734-741.
Google Scholar | Crossref | Medline32. WHO Classification of Tumours Editorial Board . Thoracic tumors. International Agency for Research on Cancer; 2021, (WHO Classification of tumor series, 5th ed.; vol. 5).
Google Scholar33. Lindeman, NI, Cagle, PT, Aisner, DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology. Arch Pathol Lab Med. 2018;142(3):321-346.
Google Scholar | Crossref | Medline34. Pilarski, R, Carlo, M, Cebulla, C, Abdel-Rahman, M. BAP1 Tumor Predisposition Syndrome. GeneReviews Press; 1993–2021.
Google Scholar35. Field, MG, Kuznetsov, JN, Bussies, PL, et al. BAP1 Loss Is associated with DNA methylomic repatterning in highly aggressive class 2 uveal melanomas. Clin Cancer Res. 2019;25(4):5663-5673.
Google Scholar | Crossref | Medline

留言 (0)

沒有登入
gif